NCT00296153View on ClinicalTrials.gov

Omacor and Cardiovascular Risk Factors in HIV Patients on HAART Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

November 30, 2006

Study Completion Date

October 31, 2007

Conditions
Human Immunodeficiency VirusIschemic Heart Disease
Interventions
DRUG

Omega-3-acid ethyl esters 90

Omacor capsule 1000mg x 4 per day. Duration 12 weeks

Trial Locations (1)

9100

Aalborg Hospital, Department of Nephrology, Aalborg

Sponsors

Lead Sponsor

Pronova BioPharma
All Listed Sponsors
collaborator

Aalborg University Hospital

OTHER

lead

Pronova BioPharma

INDUSTRY